Skip to search formSkip to main contentSkip to account menu

Falirytmin

Known as: N,N'-bis-(3-(2'-ethoxyphenoxy)-2-hydroxypropyl)-ethylenediamine 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Ethylenediamines

Narrower (1)

Falirytmin dihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
[Biotransformation and excretion of N,N'-bis(3-(2-ethoxyphenoxy)-2-hydroxypropyl)ethylenediamine dihydrochloride (Falirytmin) in rats].
Falirytmin (1) was metabolized in rats almost completely. Besides small amounts of 1 in urine and feces 18 metabolites could be… 
1990
1990
[Quantitative determination of N,N-bis[3-2'-ethoxyphenoxy)-2-hydroxypropyl]ethylenediamine dihydrochloride (Falirytmin) in plasma].
1980
1980
[The pharmacokinetics of falirytmin given orally to humans].
1976
1976
[Quantitative determination of N,N'-bis-[3-(2'-ethoxyphenoxy)-2-hydroxypropyl]-ethylenediamine dihydrochloride (Falirytmin) in blood].
1976
1976
[Pharmacokinetic parameters of N,N'-bis-(3-(2'-ethoxyphenoxy)-2-hydroxypropy1)-ethylenediamine (Falirytmin) in rabbits].
1976
1976
[Antiarrhythmic, cardiovascular and toxic actions of N,N'-bis-[3-(2'-ethoxyphenoxy)-2-hydroxypropyl]-ethlenediamine (Falirytmin) as compared to propranolol, quinidine and ajmaline].
1976
1976
[Inhibition of adrenergic beta receptors by N,N'-bis-[3-(2'ethoxyphenoxy)-2-hydroxypropyl]-ethylenediamine (Falirytmin) as compared to propranolol].
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)